Asia Fresh News

Asia Fresh Stories

Archive for April 22nd, 2015

Trade Growth and Drive For Efficiency Tops Agenda At Sea Asia Opening Day

leave a comment »

SINGPAORE, April 21, 2015 /PRNewswire/ — Leaders at today’s opening of Sea Asia 2015 have highlighted the need for shipping companies to drive greater operational efficiencies in order to capture trade growth opportunities and survive the short-term challenges of today’s environment.
Minister for Transport and Second Minister for Defence Mr Lui Tuck Yew speaking at the Sea Asia 2015 opening ceremony today.
Minister for Transport and Second Minister for Defence Mr Lui Tuck Yew speaking at the Sea Asia 2015 opening ceremony today.

Taking place in Singapore until Thursday 23 April, Sea Asia brings together leaders of the maritime and offshore industries to discuss, debate and analyse challenges and opportunities facing the sector.

Speaking at the opening ceremony, Minister for Transport and Second Minister for Defence Mr. Lui Tuck Yew said Asia is fast becoming the engine of global growth and that the maritime industry needs to be prepared.

“All signs suggest that Asia will drive global shipping in the coming years. Shipping patterns have shifted and will continue to move towards Asia. In 2014, Asia accounted for almost 80 per cent of global container throughput.”

Experts on the panel of the Sea Asia Global Forum agreed with Mr. Lui and commented that growing economies present exciting opportunities for shipping and the broader maritime sector, particularly in Asia.

However, they added that with a number of challenges on the horizon, companies must operate as efficiently as they can to survive.

Managing Director Pacific International Lines Mr. S.S Teo said: “The shipping industry is facing some short term pressure which means one has to be as efficient as they can.

“It’s not just about the size, it’s also about how you well you run your services with most efficient ships using technology and IT,” he said.

Precious Shipping Ltd Managing Director Mr. Khalid Hashim agreed, saying: “It’s a question of survival over the next few years and to do this companies need to take action now to drive down costs and improve efficiencies.

“They need to scrap, get rid of any non-core assets and raise finance to survive the current challenges that the industry is facing.

Overcapacity is one of the short-term challenges which is being compounded by softening demand in key markets, said Mr. Hashim.

“China’s steel production was flat last year while demand for coal dropped 40 per cent. These trends are bad news for the dry bulk shipping market which transports these key commodities.”

The Sea Asia Global Forum panellists commented that while the industry is facing challenges, they are optimistic for the future.

Chairman of BW Group Mr. Andreas Sohmen-Pao said: “The unprecedented growth of the middle class in emerging markets, cheaper energy and raw materials, and rapid technological advances make me very optimistic for the medium-term, even though there are plenty of near-term challenges.”

Mr. Teo added that by 2030, 50 per cent of the world’s middle class is expected to be in Asia.

“At the same time, trade agreements such as the ASEAN Economic Community and the Trans-Pacific-Partnership will drive the movement of goods here in Asia and around the world — a real opportunity for the shipping sector,” he said.

Maritime industry leaders highlighted the importance of coming together to discuss and analyse the industry’s opportunities and challenges and pointed to Sea Asia as a key platform to do this.

Seatrade Chairman Chris Hayman said: “Since the first event in 2007, Sea Asia has trebled in size and this year we are expecting over 14,000 attendees at Sea Asia from around 70 countries.

“This event gives us all the opportunity to hear the voice of Asian shipping, as the leaders of the industry in this region, and their counterparts from around the world, tell us what they are expecting from the complex environment they now face,” he said.

For more information, please contact:

Sharon Chan
Email: sharon.chan@bbspr.com.sg
Mobile: +65 9759 9528
DID: +65 6239 4107

About Sea Asia

Sea Asia, an international conference and exhibition for the maritime and offshore industries, is returning for the 5th edition from 21 to 23 April 2015 at the Marina Bay Sands®, Singapore. Sea Asia serves as a focal point for both the global and local maritime communities to network, explore new businesses, and showcase the latest maritime innovations, equipment and services. Co-organised by Seatrade and the Singapore Maritime Foundation, Sea Asia is an anchor event held in conjunction with the Singapore Maritime Week and is well-attended by the most influential and respected leaders in the industry. The 3-day Sea Asia conference will bring forth the latest discussion and debates on key trends, opportunities and challenges facing the maritime industry.

Sea Asia is supported by principal sponsors Anglo-Eastern Ship Management Ltd, DP World UAE Region, Executive Ship Management, Lloyd’s Register, Neptune Orient Lines (NOL), Sohar Port & Freezone, as well as sponsors ABS, Admiralty, AXSMARINE, ClassNK, DNVGL, G Travel, Hempel, JTJB LLP, Keppel Offshore & Marine, LUKOIL Marine Lubricants, M3 Marine Group Pte Ltd, Mobil Industrial Lubricants, Pacific International Lines (Pte) Ltd, PANAMA MARITIME AUTHORITY, WORLDWIDE LEADER FLAG STATE, PSA Corporation Limited, QBE INSURANCE (INTERNATIONAL) LIMITED, Singtel, The Standard Club Asia Ltd, Veritas Petroleum Services, and Zamil Offshore.

For more information, please visit http://www.sea-asia.com.

About Seatrade

Seatrade provides a range of global events, websites and publications that covers every aspect of the cruise and maritime industries, bringing together key people to encourage innovation and to produce powerful learning, networking and promotional platforms. Founded in 1970, Seatrade was acquired recently in 2014 by UBM, the world’s second largest media and event organiser. Seatrade sits with the UBM EMEA, which connects people and creates opportunities for companies to develop new business, meet customers, launch new products, promote brands and expand markets. Operating in over 23 countries, UBM EMEA organizes many of the world’s largest, most important exhibitions, conferences, awards, directories, websites and publications in a wide variety of industries.

For full details about this event, visit http://www.sea-asia.com. Find out more about Seatrade and UBM, visit http://www.seatrade-global.com/seatrade-global-information/about-seatrade.html and http://ubmemea.com/.

About the Singapore Maritime Foundation

Established in 2004, the Singapore Maritime Foundation (SMF) is a private sector-led organisation that seeks to develop and promote Singapore as an International Maritime Centre (IMC). As the representative voice for the commercial players of the maritime industry, SMF seeks to forge strong partnerships with the public and private sectors of the maritime industry. SMF spearheads initiatives to promote the diverse clusters of the maritime industry in Singapore and at international frontiers, and to attract young talents to join the sector. SMF is directed by its Board of Directors which comprises prominent leaders in the Singapore maritime community. For details, visit http://www.smf.com.sg.

Photo – http://photos.prnasia.com/prnh/20150421/8521502493
Source: Seatrade Communications

Written by asiafreshnews

April 22, 2015 at 6:08 pm

Posted in Uncategorized

NSFOCUS DDoS Threat Report Reveals IoT-Connected Devices Contributing to the Rise in SSDP-based Reflection Attacks

leave a comment »

-Report States Online Gaming and Entertainment Sectors Continue to be High on the Target List and Attackers Are Becoming More Sophisticated

SINGAPORE /PRNewswire/ — (RSA, Moscone Center, Booth #832) – NSFOCUS released its bi-annual DDoS Threat Report today, revealing new attack findings and rising threats that organizations should be aware of throughout 2015. As the tide of distributed denial-of-service (DDoS) attacks continues to expand, the rise of the Internet of Things (IoT) and the influx of network connected devices, such as webcams and routers, are leading to the growth of Simple Service Discovery Protocol (SSDP)-based amplification attacks. To download the entire report, visit HERE.

KEY FINDINGS:
Results of statistical analysis and key observations are based on data from actual incidents of DDoS attacks that occurred during the second half of 2014. This data was collected from a mix of global enterprises, Internet service providers, regional telecom operators and Internet hosting companies.

  • The rise of IoT-connected devices responsible for an increase in SSDP reflection attacks: With the proliferation of the Internet of Things, any network-connected device with a public IP address and vulnerable operating system will increase the number of devices that could be used to launch SSDP–based reflection attacks. This particular type of DDoS attack was seen as the second most dominant threat, after NTP-based attacks, in 2H2014. More than 30 percent of compromised SSDP attack devices were network-connected devices such as home routers and webcams. Findings also revealed that globally, more than 7 million SSDP-controlled devices could potentially be exploited.
  • Attackers are becoming smarter: While 90 percent of DDoS attacks lasted less than 30 minutes, one attack lasted 70 hours. This shorter attack strategy is being employed to improve efficiency as well as distract the attention of IT personnel away from the actual intent of an attack: deploy malware and steal data. These techniques indicate that today’s attacker continues to become smarter and more sophisticated.
  • Online retailers, media and gaming remain top targets: As retailers, entertainment and gaming companies increasingly employ online environments, consumers demand the highest level of quality of service. By slowing down or flooding these servers, attackers look to take advantage of online businesses through a variety of means, including blackmail, unfair business competition or asset theft.

Yonggang Han, COO of global business, NSFOCUS, said:
“We are watching the evolution of attack technologies that amount to nothing less than ‘bullying’ (flood attacks) and ‘leveraging’ (resource exhaustion) tactics that enhance the impact by exploiting network bandwidth. To counteract these assaults, organizations must look to traffic- cleaning devices in conjunction with other security protocols.”

Visit us at RSA2015, April 20-23 – South Hall, Booth# 832

About NSFOCUS
NSFOCUS is a global provider of distributed denial of service (DDoS) mitigation solutions. Founded in 2000, the company provides enterprise-level, carrier-grade solutions for DDoS mitigation, Web security and enterprise-level network security. With more than a decade of experience in DDoS research and development and mitigation, NSFOCUS has helped customers around the world maintain high levels of Internet security, website uptime and business operations to ensure that their online systems remain available. The NSFOCUS Anti-DDoS System (ADS) empowers customers to find and fend off a variety of incidents, from simple network layer attacks to more sophisticated and potentially damaging application-layer attacks, all while guaranteeing legitimate traffic gets through to networks and corporate-critical systems. For more information, visit www.nsfocus.com.

Source: NSFOCUS

Written by asiafreshnews

April 22, 2015 at 5:24 pm

Posted in Uncategorized

The Debut Show of Innovative Biologics Packaging Solutions Showcase

leave a comment »

SHANGHAI  /PRNewswire/ — In recent years, Biologics has gradually become an important driving force for the global development of the pharmaceutical industry. With numerous patents of biopharmaceutical reaching the deadline, the original research pharmaceutical companies are looking for ways to extend patent protection , strengthening patent barriers; biosimilar companies are active in enhancing competitiveness  to enter this lucrative market. As an integral part of biological agents, packaging materials and drug delivery systems are important for promoting the new drugs which are sold in the market to ensure drug safety, effectiveness and to enhance value-added products, therefore, more and more biopharmaceutical companies have paid more attention to the packaging materials and drug delivery systems. Design and manufacture of innovative packaging and new biologics delivery system will become a new field of pharmaceutical packaging industry.

The Debut Show of Innovative Biologics Packaging Solutions Showcase
The Debut Show of Innovative Biologics Packaging Solutions Showcase

Facing the target customers, improve brand image

InnoPack China as the flagship event of pharmaceutical packaging industry in Asia Pacific, the international line brand packaging materials will attend to the exhibition, to be held May 2015.6.24-26 “Innovation Biologics Packaging Solutions Showcase Show” event in Shanghai New International Expo Center during the exhibition, biologics innovative packaging components and related drug delivery systems will be shown, decision-making who in charge of research and development, procurement, production, technology and quality of pharmaceutical companies will be attracted. That will provide the bio-pharmaceutical companies with a one-stop packaging solutions for the medical packaging suppliers and biological exchanges and cooperation in the pharmaceutical industry。

A great place to show, through the four exhibitions

The Show of Innovative Biologics Packaging Solutions Showcase adjacent to the main entrance which audience crowded place, lots of high-quality domestic and international leading supplier of packaging materials will be there, the powerful combination of complementary advantages and all of these will design the professional packaging solutions which for biologics, vaccines, blood products, genetic engineering business to enhance the brand image and influence, while connectivity pharmaceutical packaging materials Exhibition (InnoPack China) Chinese biopharmaceutical and Technology Exhibition (BioPh China), the world’s biochemistry, analytical instruments and laboratory equipment China Exhibition (LABWorld China), the world’s pharmaceutical contract customization China Exhibition (ICSE China) four galleries throughout the biopharmaceutical industry chain.

InnoPack Show Map
InnoPack Show Map

CHINA CHAMBER OF COMMERCE OF MEDICINES & HEALTH PRODUCTS IMPORTERS & EXPORTERS

Shanghai UBM Sinoexpo International Exhibition Co.Ltd

Show detailed consultation Registration:
Tel: 010-5803 6338 \ 021-33392255
Contacts: Miss Qu, Miss Feng
Email: quao@cccmhpie.org.cn
iris.feng@ubmsinoexpo.com
Official website: www.p-mec.cn

Photo – http://photos.prnasia.com/prnh/20150420/0861503102-a
Photo – http://photos.prnasia.com/prnh/20150420/0861503102-b

Source: UBM Sinoexpo
Related Links:

Written by asiafreshnews

April 22, 2015 at 5:20 pm

Posted in Uncategorized

ChinaCache Launches High Performance Cloud Cache, Leading the Content Delivery Network Industry into the Cloud Age

leave a comment »

BEIJING /PRNewswire/ — ChinaCache, the content delivery network (CDN) industry leader in China, recently announced the fully online running of its efficient cloud distribution platform high performance cloud cache (HPCC), on its entire network. HPCC is the next generation of cloud computing technology based on a CDN foundation core platform independently developed by ChinaCache. This marks ChinaCache’s success in transformation from traditional file distribution mode CDN to a cloud distribution platform, beginning a new chapter for the CDN cloud age.

From its early natural growth period relying on manual scheduling experience, followed by offering edge cache service and rich peripheral support system through traffic scheduling service, CDN has moved to the CDN cloud age of cloud-enabled node resource, Internet traffic intelligent scheduling, content hierarchical caching, and multi-IDC management support.

ChinaCache’s efficient cloud distribution platform HPCC is a new generation of platform technology based on this evolution. A new generation of CDN platform, built by the high-performance proxy server and cloud storage system on the HPCC platform, is designed to reduce resource cost and improve user experience, with its core features of distributed systems, business storage separation, node resource pooling, and content intelligent aware function. ChinaCache’s single node cloud platform is many times faster compared with similar products in terms of performance, making Internet applications even faster, significantly boosting user experiences.

With the launching of ChinaCache’s efficient cloud distribution platform HPCC, the CDN market in China will gradually enter into the cloud computing era, helping to better solve China’s current Internet congestion issues, greatly improving user access response speed, and making content transmission faster and more stable.

HPCC will provide services such as page acceleration, file distributed download, video streaming media, and mobile Internet to ChinaCache’s core business, to substantially increase many indicators in terms of resource utilization, back to the source bandwidth, operational cost, and customer cost, while offering customers more variety of differentiated value-added services.

A large domestic microblogging website has been operated stably in ChinaCache’s efficient cloud distribution platform HPCC for more than four months, with remarkable results:

  • More balanced Internet flow scheduling, with each node resource utilization rate floating by not higher than 10%;
  • The number of single node file storage exceeding 1 billion, with access hitting ratio increased by 20%;
  • With improved hitting rates, back to the source rate lowers by over 10%;

At present, ChinaCache’s CDN network has been carrying out page display of 9.6 billion times a day and video content browsing and downloading of more than 1 billion times, producing system and user logs of more than 130 TB magnitude every day. The online running of the efficient cloud distribution platform HPCC will surely greatly improve ChinaCache’s service platform in terms of overall technology level, business delivery capacity, and service quality, also bringing new development momentum for the CDN industry.

Source: ChinaCache

Written by asiafreshnews

April 22, 2015 at 5:19 pm

Posted in Uncategorized

Oil And Gas ‘Heroes’ To Take Centre Stage At 18th Asia Oil And Gas Conference

leave a comment »

KUALA LUMPUR, Malaysia /PRNewswire/ — Continuing to provide reliable and affordable energy often requires strong leadership and bold decision-making from key executives at top oil and gas companies. Those outstanding individuals that are driving the industry forward will be sharing their visions of the future at a major conference in Asia next month.

The 18th Asia Oil and Gas Conference, which will take place again in Asia’s oil and gas capital Kuala Lumpur from 17 – 19 May, brings these ‘Heroes’ of the oil and gas industry together to reflect on current industry issues and give their opinions on how to address the challenges that exist both now and in the future.

The inaugural CEO Strategic Dialogue and the Energy Hotspot sessions are just two of the many sessions in which top-level industry decision-makers will explore the opportunities for the Asian oil and gas industry in the face of challenges arising from the current oil price environment. Under the theme “Realising Opportunities Amidst Challenges,” answers will be sought on trending topics such as novel technology exchange, collaboration strategies, monetisation of unconventional resources and addressing tensions between suppliers and consumers of gas to highlight a few.

Everyone, both from exporting and importing countries, is experiencing the current tremors. Downstream session speaker Michio Ikeda, EVP and Director, JX Nippon Oil and Energy Corporation commented: “The Japanese oil industry is faced with a big challenge. It should look at the reality and take appropriate measures timely enabling it to survive the demand decline and capture growth opportunity. It should be done today lest it be too late and its outcome too disruptive.”

This uncertainty has rippled across the globe, as evidenced by Ramon S. Ang, President and CEO of PETRON CORPORATION: “My wish would be for more stability, more certainty in which way oil prices go. What makes this industry very challenging is not knowing just how far prices might fall, or when they will fall further. Of course we all know that as long as there is geopolitical instability – and a changing attitude to fossil fuels and the issue of climate change and sustainability – uncertainty will continue to prevail. To lessen its impact, we try to anticipate what might happen and tighten the screws in areas where we have more control. In that way we’re better prepared to meet the challenges – those we can and cannot anticipate.”

Technological innovation will play a vital role going forward, according to Dr. Rajeev Gautam, President & CEO, UOP: “The only thing within our power is to embrace technology and innovation as a hedge against volatility by having the most productive and efficient facilities we can. This will give us greater control over the risks and better position the industry for the future.” Dr. Gautam will be speaking in the session on Technology breakthroughs and impact at AOGC 2015.

Regulators, operators and the service sector can all come together to help the oil and gas industry become more competitive, reducing costs and driving structural improvements. For Iain Lo, Chairman, Shell Malaysia, such collaboration is the key to success: A willingness to share best practice and learn from each other so we can all strive for best-in-class performance, and an openness to simplify work processes between regulators, operators and service providers – these are a few examples of the type of things we will need to improve the efficiency of our industry as a whole.” Attendees at AOGC 2015 will be able to hear more from Mr. Lo in his keynote presentation on the upstream sector.

A final note of optimism is provided by Dr. Gautam of UOP:

The future of our industry is very bright. The world’s population is continuing to grow, and an unprecedented number of people will be entering the middle class over the next generation. Oil and gas will continue to meet most of the demand for fuel, energy and petrochemicals. Forums such as AOGC will inform the actions we take today, ensuring that the world will continue to become more prosperous.

About Asia Oil and Gas Conference

The Asia Oil and Gas Conference (AOGC) was first held in 1996 and has since become an annual gathering and platform for networking opportunities and forging business partnerships amongst the oil and gas fraternity in the Asia-Pacific region.

Petroliam Nasional Berhad (PETRONAS), the national oil and gas corporation of Malaysia, has taken the lead to manage and organise this premier event every year.

Over the years the conference has evolved into an important annual gathering for key industry leaders, industry experts and specialists, along with key decision-makers, to reflect on current issues, exchange ideas and opinions, discuss and deliberate challenges and solutions confronting the oil and gas industry. The conference has also become a platform for key industry players to strategically and effectively positions themselves in the wake of daunting challenges.

AOGC 2015 will take place from 17 – 19 May 2015 in Kuala Lumpur, Malaysia. PETRONAS is the host organisation for the event. Further information can be found at: http://aogc.com.my/index.html

SOURCE: Organising Committee, Asia Oil and Gas Conference 2015

Written by asiafreshnews

April 22, 2015 at 4:04 pm

Posted in Uncategorized

Vinmec Makes Varian Image-Guided and RapidArc Treatments Available to Cancer Patients in Vietnam

leave a comment »

HANOI, Vietnam /PRNewswire/ — Vinmec International Hospital here in Hanoi has commenced offering cancer patients advanced radiotherapy with a new Clinac® iX medical linear accelerator from Varian Medical Systems (NYSE: VAR).

The Clinac iX system enables the hospital to deliver intensity-modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT), and some forms of stereotactic body radiotherapy (SBRT). Equipped with Varian’s RapidArc® technology, the new accelerator can deliver treatments quickly so that more patients have access to these modern treatment techniques. The clinic is also using Varian’s Eclipse™ treatment planning software to target tumors precisely while protecting surrounding healthy tissue. Early treatments at the hospital are focusing on thoracic cancers, gynecological cancers, head & neck cancers, prostate cancers, and localized lymphoma.

“It is very important that cancer patients in this country can benefit from the most modern forms of radiotherapy,” said radiation oncologist Dr. Doan Trung Hiep, MD, MSc. “This excellent device has an advanced image guided radiotherapy system that makes it possible to deliver fast, targeted treatments to tumors even as they move and change over time. It also means we can expand the range of tumors we can target with our first stereotactic radiosurgery treatments.”

Vinmec International Hospital is the first radiotherapy center established by the Vinmec International Hospital Joint Stock Company, aimed at helping to bridge the capacity gap in the country. There are more than 90 million people in Vietnam but fewer than 30 linear accelerators are installed in the country’s hospitals. Vinmec is planning to establish up to ten private radiotherapy centers by 2020.

“We are committed to establishing a world-class radiation oncology capability in Vietnam with more modern equipment, trained clinicians and a radiotherapy education program,” said Dr. Doan Trung Hiep. “Vinmec is proud to be working with Varian to develop this treatment capability for our patients.”

Michael Sandhu, Varian’s VP global market development, said, “We are honored to be working with Vinmec to offer advanced treatment technology for the benefit of cancer patients across Vietnam. Through initiatives such as this and through our educational programs such as ‘Access to Care’, Varian is working to expand access to modern radiotherapy globally.” Varian’s first Access to Care program was launched in Vietnam earlier this year, with 15 students combining internships at local hospitals with sessions at a specially-equipped training center inHanoi.

Editorial contact:
Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, focuses energy on saving lives by equipping the world with advanced technology for fighting cancer and for X-ray imaging. The company is the world’s leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is also a premier supplier of X-ray imaging components, including tubes, digital detectors, and image processing software and workstations for use in medical, scientific, and industrial settings, as well as for security and non-destructive testing. Varian Medical Systems employs approximately 6,800 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visithttp://www.varian.com or follow us on Twitter.

Source: Varian Medical Systems

Related stocks: NYSE:VAR

Related Links:

Written by asiafreshnews

April 22, 2015 at 3:29 pm

Posted in Uncategorized

FMC Corporation Completes Acquisition of Cheminova A/S

leave a comment »

PHILADELPHIA /PRNewswire/ — FMC Corporation (NYSE: FMC) today announced that it has completed the closing of its acquisition of Cheminova A/S, a multinational crop protection company based inDenmark and a wholly-owned subsidiary of Auriga Industries A/S. The companies announced the signing of a definitive acquisition agreement on September 8, 2014, and have now satisfied all necessary conditions and regulatory approvals.

Logo – http://photos.prnewswire.com/prnh/20111101/NE97440LOGO

FMC completed the acquisition of Cheminova for an aggregate purchase price of approximately $1.8 billion, including assumption of debt. FMC expects the transaction to be accretive to adjusted earnings in the first full year following the acquisition.

“The acquisition of Cheminova is fully aligned with our corporate strategy to focus FMC’s portfolio on agriculture, health and nutrition end markets,” said Pierre Brondeau, FMC president, CEO and chairman. “Cheminova has a highly complementary product portfolio and geographic footprint and follows a similar strategic approach to FMC in applying technology to deliver solutions to its customers. This transaction will broaden our Agricultural Solutions portfolio and significantly strengthen our market access.”

Brondeau continued, “Cheminova gives us direct market access to key countries in Europe and enhances our customer reach in India, Australia and throughout Latin America, bringing greater balance to our agricultural business. Its technology will enable us to expand FMC’s position in existing crops; accelerate access to additional crops, such as cereals; and strengthen our offerings to customers, especially in sugarcane, soybeans and cotton. We expect to further enhance our innovation pipeline and generate significant new revenue opportunities for the combined business.”

FMC has been realigning its business portfolio in recent years to expand its position in the crop protection market. With the acquisition of Cheminova, and the divestiture of the Alkali Chemicals business completed on April 1, 2015, FMC Agricultural Solutions is expected to represent approximately three quarters of the company’s total revenue, up from less than 40 percent as recently as 2009.

The company will provide integration updates during quarterly earnings calls and at its upcoming Investor Conference on May 11, 2015.

About FMC Corporation
FMC Corporation is a specialty company serving agricultural, industrial and consumer markets globally for more than a century with innovative solutions, applications and quality products. In 2014, FMC had annual sales of approximately $3.3 billion from continuing operations (excluding sales from the divested Alkali Chemicals business). In 2014, Cheminova had sales of DKK 6.8 billion. FMC employs approximately 7,000 people (including employees from Cheminova) throughout the world and operates its businesses in three segments: FMC Agricultural Solutions, FMC Health and Nutrition and FMC Lithium. For more information, visitwww.FMC.com.

Safe Harbor Statement under the Private Securities Act of 1995: Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning specific factors described in FMC Corporation’s 2014 Form 10-K and other SEC filings. Such information contained herein represents management’s best judgment as of the date hereof based on information currently available. FMC Corporation does not intend to update this information and disclaims any legal obligation to the contrary. Historical information is not necessarily indicative of future performance.

Source: FMC Corporation

Related stocks: NYSE:FMC

Written by asiafreshnews

April 22, 2015 at 2:39 pm

Posted in Uncategorized

Novogen Conducts Private Placement and Announces Rights Offering to Shareholders

leave a comment »

— A$15.5M private placement to US institutional investors
— Rights Offering to be available for eligible shareholders
— Raising to fund significant growth plans

SYDNEY /PRNewswire/ — Novogen Limited (ASX:NRT; NASDAQ:NVGN) (“Company” or “Novogen”), an Australian/US biotechnology company, advises that it has entered into definitive agreements today to issue approximately 51 million fully-paid ordinary shares plus one attaching 6-month option and half of one attaching 5-year option for every ordinary share issued, to institutional investors in the United States in a private placement for aggregate gross proceeds of approximately AU$15,500,000 (“Placement”). The closing of the Placement is expected to occur on or about 24 April 2015 and is subject to satisfaction of customary closing conditions. The issue of the attaching options under the Placement is subject to shareholder approval.

HC Wainwright & Co. is the exclusive placement agent for the Placement.

To provide an opportunity for existing shareholders of the Company to participate at the same price, the Company will be undertaking a 1 for 6 non-renounceable rights issue offering of fully-paid ordinary shares to raise up to a maximum of approximately A$15,000,000 (“Rights Issue”). Participants will also receive, for no additional cash consideration, one 6-month option and half of one 5-year option for every one share issued under the Rights Issue. The Rights Issue will be open to eligible shareholders who hold shares as at 5.00pm (AEST) on Friday 1 May 2015 (“Record Date”). The Rights Issue is expected to close at 5.00pm (AEST) on 29 May 2015. Eligible shareholders will be invited to apply for additional shares together with attaching options in excess of their entitlement.  The directors have reserved the right to place any shortfall within 3 months of close of the Rights Issue.

Lodge Partners Pty Ltd (http://www.lodgepartners.com.au/) and HC Wainwright & Co. will co-manage the placement of any shortfall in the Rights Issue.

Under the terms of the Placement and the Rights Issue, the Company proposes to raise up to AU$30,500,000 through the issue of an aggregate of up to approximately 98.7 million fully-paid ordinary shares at a price of AU$0.30 each, comprising approximately 51 million shares under the Placement and up to approximately 47 million shares under the Rights Issue.

The AU$0.30 issue price represents a 10% discount to the 5-day VWAP leading up to Friday 17 April 2015.

The Company has also in aggregate agreed to grant to the investors under both the Placement and the Rights Issue, for no additional cash consideration:

  • 6-month options to purchase up to an aggregate of approximately 98 million ordinary shares at an exercise price of A$0.30 per option; and
  • 5-year options to purchase up to an aggregate of approximately 49 million ordinary shares at an exercise price of A$0.40 per option.

Issuance of the options under the Placement is subject to Novogen receiving shareholder approval at a general meeting, which is expected to be held in June 2015. The issuance of the options under the Rights Issue will not require shareholder approval. The exercise price of the options will be subject to future adjustment for various events required under ASX Listing Rules, such as stock splits.

The securities offered and sold in the Placement have not been registered under the Securities Act of 1933, as amended, or any United States state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Company has agreed to cause the registration in the United States of ADRs representing the ordinary shares purchased by the United States investors and the shares underlying the options for resale in the United States.

The Company intends to use the proceeds of the Placement and the Rights Issue for ongoing and future research programs into the development of the Company’s drug pipeline and for working capital purposes.

Notices containing further details in relation to the Rights Issue, including the proposed timetable, will be sent to shareholders and optionholders of Novogen shortly. A copy of those notices will also be made available on the ASX website at asx.com.au under the code “NRT” and the Company’s website at www.novogen.com.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities in any jurisdiction.

Graham Kelly, Novogen Group CEO, said, “The Company is about to enter a significant growth phase. The last two years have been about laying the groundwork with our two technology platforms. That work has brought us now to a position of being in a position to exploit the considerable opportunities that those two proprietary drug technology platforms offer.

“We have identified 3 needs for funding. The first is to provide a runway for our 3 lead oncology candidate drugs to put them in a position (Phase 1b/2a, Phase 0) where we might expect to see objective evidence of clinical benefit.

“The second need is to build on the highly promising data we are seeing with both technology platforms in a range of non-oncology fields. Five such programs are underway, each with the potential to develop into major new areas of therapeutic opportunity.

“The third need is to retain our independence in order to maximize shareholder value. Novogen has the opportunity to grow quickly into a significant drug discovery company. The further we take that opportunity as an independent company, the greater the shareholder value. I believe that the Company has the intellectual property and the management expertise to achieve its goal of becoming a major player in the international biotechnology sector, and the fund-raising that we have announced today is key to that,” Kelly added.

About Novogen Limited

Novogen is a public, Australian-US drug-development company whose shares trade on both the Australian Securities Exchange (‘NRT’) and NASDAQ (‘NVGN’). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been designed to kill the full heterogeneity of cells within a tumor, but with particular activity against the cancer stem (tumor-initiating) cell.

The ATM compounds target the micro-filament component of the cancer cell’s cytoskeleton and have been designed to combine with anti-microtubule drugs (taxanes, vinca alkaloids) to produce comprehensive and fatal destruction of the cancer cell cytoskeleton.

The Company pipeline comprises two SBP drug candidates (TRXE-002, TRXE-009) and one ATM drug candidate (Anisina).

Further information is available on our website www.novogen.com.

For more information please contact:

Corporate Contact

Dr. Graham Kelly

Executive Chairman & CEO

Novogen Group

Graham.Kelly@novogen.com

+61 (0) 2 9472 4100

Media Enquiries

Cristyn Humphreys

Chief Operating Officer

Novogen Group

Cristyn.Humphreys@novogen.com

+61 (0) 2 9472 4111

Forward Looking Statement

All statements other than statements of historical fact included in this announcement including, without limitation, statements regarding future plans and objectives of Novogen Limited (“Novogen”) are forward-looking statements. When used in this announcement, forward-looking statements can be identified by words such as ‘may’, ‘could’, ‘should’, ‘would’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’ or ‘intends’ and other similar words that involve risks and uncertainties.

Such statements relate to future events and expectations and as such involve known and unknown risks and uncertainties. These risks and uncertainties include, among other things, market conditions, weather risks, economic and political risks.

These statements are based on an assessment of present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this announcement, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of Novogen, its directors and management, which could cause Novogen’s actual results to differ materially from the results expressed or anticipated in these statements.

Novogen cannot and does not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements. Actual results, actions, and developments may differ materially from those expressed or implied by those forward-looking statements depending on a variety of factors.

Novogen does not undertake to update or revise forward- looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this announcement, except where required by applicable law and stock exchange listing requirements.

Source: Novogen Ltd
Related Links:

Written by asiafreshnews

April 22, 2015 at 11:55 am

Posted in Uncategorized

Micrel Releases New RF Receivers Offering Best-in-Class Sensitivity And Power Consumption

leave a comment »

SAN JOSE, Calif., April 20, 2015 /PRNewswire/ — Micrel Inc., (Nasdaq:MCRL), an industry leader in high-performance Linear and Power solutions, LAN and timing and communications solutions, today introduced the MICRF229 and the MICRF230, low-power, 400MHz to 450MHz, super-heterodyne, image reject, OOK/ASK receivers. Both devices feature -112dBm sensitivity at a data rate of 1kbps and operate from 3.5V to 5.5V. They consume less than 6mA of current when receiving data continuously and are aimed at remote keyless entry (RKE), garage door openers, home automation, and other low-power, low data rate applications. The MICRF229 and MICRF230 are currently available in volume quantities, with 1,000 quantity pricing starting at $1.6. Samples can be ordered at: https://www.samplecomponents.com/scripts/samplecenter.dll?micrel

“The global home automation and control market is slated for fast growth. These markets include security and lighting control,” noted Brain Hedayati, vice president of marketing for linear and power solutions at Micrel. “Micrel’s new RF products continue to address this explosive market with our new low power, cost effective and robust RF solutions.”

The MICRF229 and MICRF230 require only a crystal and a minimum number of external components to implement. The MICRF229 has an auto-poll feature that allows power consumption to be reduced to under 0.5mW while the receiver awakes and polls for a valid signal before awaking the microcontroller. The MICRF230 employs an optional Squelch feature which disables the data output until valid bits are detected, allowing the microcontroller to remain in low-power shutdown mode drawing only 0.5uA of supply current to save power. The MICRF229 and MICRF230 are specified with an operating temperature range of -40°C to +105°C and are offered in a 16-Pin 4.9mm x 6.0mm QSOP package.

About Micrel, Inc.
Micrel, Inc. is a leading global manufacturer of IC solutions for the worldwide analog, Ethernet and high-bandwidth markets. The Company’s products include advanced mixed-signal, analog and power semiconductors; high-performance communication, clock management, MEMS-based clock oscillators and crystal-less clock generators, Ethernet switch and physical layer transceiver ICs. Company customers include leading manufacturers of enterprise, consumer, industrial, mobile, telecommunications, automotive, and computer products. Corporation headquarters and state-of-the-art wafer fabrication facilities are located in San Jose, CA, with regional sales and support offices and advanced technology design centers situated throughout the Americas, Europe and Asia. In addition, the Company maintains an extensive network of distributors and reps worldwide. Web: http://www.micrel.com.

Source: Micrel, Inc.

Written by asiafreshnews

April 22, 2015 at 12:34 am

Posted in Uncategorized

Global Strategic Partners Merck and Pfizer Initiate Phase III Study with Avelumab* in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer

leave a comment »

DARMSTADT, Germany and NEW YORK, April 20, 2015 /PRNewswire/ —

Not intended for UK-based media

First of several registration trials expected to start in 2015 for the alliance between Merck and Pfizer
Initiation and first patient treated in Phase III clinical study recruiting across approximately 290 sites in more than 30 countries
The primary endpoint of the study is overall survival (OS) in patients with programmed death-ligand 1 positive (PD-L1+) stage IIIb/IV non-small cell lung cancer (NSCLC) who have experienced disease progression after receiving a prior platinum-containing doublet therapy

Merck and Pfizer today announced the initiation and first patient treated in the international Phase III study (EMR 100070-004) designed to assess the efficacy and safety of the investigational cancer immunotherapy avelumab (MSB0010718C), compared with docetaxel, in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) who have experienced disease progression after receiving a prior platinum-containing doublet therapy.

The Phase III study is an open-label, multicenter, 1:1 randomized clinical trial where patients with stage IIIb/IV NSCLC will receive either avelumab or docetaxel, regardless of PD-L1 status. Approximately 650 patients will participate across 290 sites in more than 30 countries in North America, South America, Asia, Africa and Europe. In North America, clinical trials on behalf of Merck will be conducted by EMD Serono, the company’s US and Canadian biopharmaceutical businesses. The study is part of the JAVELIN clinical trial program for avelumab.

The primary endpoint of the study is overall survival (OS) in patients with programmed death-ligand 1 positive (PD-L1+) stage IIIb/IV NSCLC who have experienced disease progression after receiving a prior platinum-containing doublet therapy. Secondary endpoints will be assessed across the entire study population regardless of PD-L1 status and include OS; overall response rate (ORR); progression-free survival (PFS); and patient-reported outcomes.

“New and innovative treatment strategies are urgently needed to improve overall survival for patients with NSCLC, and we are investigating avelumab as a potential treatment option for patients with this very difficult-to-treat disease,” said Dr. Luciano Rossetti, Global Head of R&D of Merck Serono. “The treatment of the first patient in the Phase III trial is an important milestone for our immuno-oncology alliance.”

“This trial marks the first of several registration studies we are planning to initiate this year together, and underscores our commitment to accelerating the development of medications for patients with cancer,” said Dr. Mace Rothenberg, Senior Vice President of Clinical Development and Medical Affairs and Chief Medical Officer for Pfizer Oncology. “Through this alliance, we will have the opportunity to combine the promising anti-PD-L1 antibody, avelumab, with our combined portfolios of approved and investigational oncology therapies, which may provide an exciting opportunity to potentially broaden the use of immunotherapy for patients with cancer.”

The JAVELIN clinical trial program also includes an international Phase II trial to investigate avelumab in patients with metastatic Merkel cell carcinoma; an international Phase I trial to investigate avelumab in patients with metastatic or locally advanced solid tumors, and a Phase I trial to investigate avelumab in Japanese patients with metastatic or locally advanced solid tumors with an expansion part in Asian patients with gastric cancer. The Phase I program for avelumab includes more than 840 patients treated across multiple tumor types, including NSCLC, breast cancer, gastric cancer, ovarian cancer, bladder cancer, melanoma and mesothelioma.

*Avelumab is the proposed International Nonproprietary Name (INN) for the anti-PD-L1 monoclonal antibody (MSB0010718C)

About Non-Small Cell Lung Cancer

Globally, lung cancer is the most common cause of cancer-related deaths in men and the second most common in women, responsible for almost twice as many deaths as both breast and prostate cancer combined[1]. NSCLC is the most common type of lung cancer, accounting for 85 to 90 percent of all lung cancers[2]. Locally advanced and metastatic disease account for approximately 35 to 40 percent[3]and 70 percent[4]of patients, respectively with NSCLC.

Avelumab
Avelumab (also known as MSB0010718C) is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody. By inhibiting PD-L1 interactions, avelumab is thought to enable the activation of T-cells and the adaptive immune system. By retaining a native Fc-region, avelumab is thought to engage the innate immune system and induce antibody-dependent cell-mediated cytotoxicity (ADCC). In November, 2014, Merck and Pfizer announced a strategic alliance to co-develop and co-commercialize avelumab.

JAVELIN Clinical Trial Program for Avelumab

JAVELIN is an expansive international clinical trial program exploring the use of PD-L1 inhibition with avelumab to treat multiple types of cancer. The JAVELIN clinical trial program includes a Phase III study designed to assess the efficacy and safety of avelumab compared with docetaxel in patients with stage IIIb/IV NSCLC who have experienced disease progression after receiving a prior platinum-containing doublet therapy; an international Phase II open-label multicenter trial to investigate the clinical activity and safety of avelumab in patients with metastatic Merkel cell carcinoma; an international Phase I open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity in patients with metastatic or locally advanced solid tumors; and a Phase I trial to investigate the tolerability, safety, pharmacokinetics, biological, and clinical activity of avelumab in Japanese patients with metastatic or locally advanced solid tumors with an expansion part in Asian patients with gastric cancer.

Merck-Pfizer Alliance

Immuno-oncology is a top priority for Merck and Pfizer. The global strategic alliance between Merck and Pfizer enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck. The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer’s PD-1 antibody. The companies will collaborate on up to 20 high priority immuno-oncology clinical development programs, including combination trials, many of which are expected to commence in 2015.

Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at http://www.pfizer.com.

Merck

Merck of Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of € 11.3 billion in 2014. Around 39,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Pfizer Disclosure Notice

The information contained in this release is as of April 20, 2015. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Pfizer’s and Merck’s immuno-oncology alliance involving anti-PD-L1 and anti-PD-1 therapies, clinical development plans and a target indication for avelumab (MSB0010718C) for treatment of patients with stage IIIb/IV NSCLC who have experienced disease progression after receiving a prior platinum-containing doublet therapy (the “Target Indication”) that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical study commencement and completion dates as well as the possibility of unfavorable study results; risks associated with interim data, including the risk that the final results of the Phase I study for avelumab and/or additional clinical trials may be different from (including less favorable than) the interim data results and may not support further clinical development; the risk that clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether; whether and when drug applications may be filed in any jurisdictions for any potential product candidates or combination therapies, including the Target Indication; whether and when any such applications may be approved by regulatory authorities, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of any of such product candidates or combination therapies, including the Target Indication; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the SEC and available at http://www.sec.gov and http://www.pfizer.com.

References

American Cancer Society. (2011). Global Facts & Figures Second Edition. Retrieved from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf
American Cancer Society. (2014). Lung Cancer (Non-Small Cell) [Fact sheet]. Retrieved from: http://www.cancer.org/acs/groups/cid/documents/webcontent/003115-pdf.pdf
Blumenschein, G. R., Paulus, R., Curran, W. J., Robert, F., Fossella, F., Werner-Wasik, M., Herbst, R. S., Doescher, P. O., Choy, H., & Komaki, R. (2011). Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 17, 2312-2318.
Wood, S. L., Pernemalm, M., Crosbie, P. A., & Whetton, A. D. (2013). The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer treatment reviews, 4,558-566.

Source: Merck and Pfizer

Written by asiafreshnews

April 22, 2015 at 12:22 am

Posted in Uncategorized